GlassScriptPhysician profile
Rohit Gupta
NPI 1427363654
$70,514.63
in general payments reported to CMS, 2019-2025
18 companies · $16K in 2025
The $16K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $125 · 2021: $72.16 · 2022: $3,368 · 2023: $25K · 2024: $26K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Consulting Fee: $13K · Travel and Lodging: $5,289 · Honoraria: $3,261 · Food and Beverage: $2,393 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,695.00 |
| Consulting Fee | $13,152.50 |
| Travel and Lodging | $5,288.71 |
| Honoraria | $3,261.00 |
| Food and Beverage | $2,392.52 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $53,166.96 | 2022-2025 | Acthar |
| United Therapeutics Corporation | $7,995.98 | 2023-2025 | Tyvaso, Remodulin |
| Ani Pharmaceuticals, INC. | $3,466.14 | 2023-2025 | Purified Cortrophin Gel |
| Incyte Corporation | $2,362.50 | 2025 | |
| Nabriva Therapeutics, Plc | $2,158.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.72 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.00 | 2020-2023 | |
| Vertex Pharmaceuticals Incorporated | $300.00 | 2023 | |
| Genentech USA, INC. | $118.80 | 2019 | |
| Orthofix Medical, INC. | $102.21 | 2025 | Osteostrand Plus |
| Genzyme Corporation | $57.32 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $49.42 | 2024 | Fasenra |
| La Jolla Pharmaceutical Company | $21.41 | 2025 | Giapreza |
| Amgen INC. | $17.70 | 2025 | Tezspire |
| Ucb, INC. | $16.28 | 2024 | Briviact |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $14.84 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.